Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular and clinical traits of HER2-low breast cancer patients and their relationship with neoadjuvant treatment effectiveness.

European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) - 1 May 2025

Zhao Wei, Zhang Mingxiang, Zhu Bohui, Pan Yueyin, Sun Yiyuan

Abstract excerpt

BACKGROUND: We aimed to investigate the clinical and molecular characteristics of different degrees of human epidermal growth factor receptor 2 (HER2) protein expression in HER2-negative breast cancer and the related factors affecting the efficacy of neoadjuvant chemotherapy in HER2-low breast cancer patients. METHODS: The study endpoint was pathological complete remission (PCR). Blood specimens and fresh cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Class I Phosphatidylinositol 3-Kinases

Share to Erb-b2 Receptor Tyrosine Kinases

Share to Exome Sequencing

Share to Follow-Up Studies

Share to Neoadjuvant Therapy

Source

Identifiers

PMID: 39808544
DOI: 10.1097/CEJ.0000000000000924

Genes

PIK3CA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular and clinical traits of HER2-low breast cancer patients and their relationship with neoadjuvant treatment effectiveness.PMID 39808544Read ↗

Genomic Alterations of Tumors in HER2-Low Breast Cancers.Semantic proximity Read ↗

Clinical Significance and Genetic Characteristics in HER2 Low Expression Tumors of Hormone Receptor Positive Breast Cancer PatientsSemantic proximity Read ↗

Clinicopathological features and prognosis of HER2 low-expression breast cancer: a single-center retrospective studySemantic proximity Read ↗

Clinical sequencing defines the somatic and germline mutation landscapes of Chinese HER2-Low Breast Cancer.Semantic proximity Read ↗

Clinical Genetic Features and Neoadjuvant Chemotherapy Response in HER2-Low Breast Cancers: A Retrospective, Multicenter Cohort Study.Semantic proximity Read ↗

Clinical and molecular characteristics of HER2-low triple-negative breast cancer: insights from multi-omics analysisSemantic proximity Read ↗

Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas.Semantic proximity Read ↗

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancerSemantic proximity Read ↗

Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancerSemantic proximity Read ↗

[Biological characteristics of triple negative breast cancer with low expression of HER2].Semantic proximity Read ↗

Molecular characteristics and prognosis of triple negative breast cancer stratified by HER2 status.Semantic proximity Read ↗

Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.